ATE538652T1 - Synergistische pharmazeutische kombination für die behandlung von krebs - Google Patents

Synergistische pharmazeutische kombination für die behandlung von krebs

Info

Publication number
ATE538652T1
ATE538652T1 AT07735911T AT07735911T ATE538652T1 AT E538652 T1 ATE538652 T1 AT E538652T1 AT 07735911 T AT07735911 T AT 07735911T AT 07735911 T AT07735911 T AT 07735911T AT E538652 T1 ATE538652 T1 AT E538652T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
pharmaceutical combination
synergistic pharmaceutical
synergistic
Prior art date
Application number
AT07735911T
Other languages
English (en)
Inventor
Maggie Rathos
Kalpana Joshi
Harshal Khanwalkar
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Application granted granted Critical
Publication of ATE538652T1 publication Critical patent/ATE538652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07735911T 2007-05-15 2007-05-15 Synergistische pharmazeutische kombination für die behandlung von krebs ATE538652T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2007/051841 WO2008139271A2 (en) 2007-05-15 2007-05-15 A synergistic pharmaceutical combination for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE538652T1 true ATE538652T1 (de) 2012-01-15

Family

ID=40002696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07735911T ATE538652T1 (de) 2007-05-15 2007-05-15 Synergistische pharmazeutische kombination für die behandlung von krebs

Country Status (18)

Country Link
US (1) US8822526B2 (de)
EP (1) EP2154971B1 (de)
JP (1) JP5688288B2 (de)
KR (1) KR101403100B1 (de)
CN (1) CN101677567B (de)
AR (1) AR066564A1 (de)
AT (1) ATE538652T1 (de)
AU (1) AU2007353129B2 (de)
BR (1) BRPI0721626A2 (de)
CA (1) CA2687204C (de)
DK (1) DK2154971T3 (de)
ES (1) ES2380129T3 (de)
IL (1) IL202014A (de)
MX (1) MX2009012155A (de)
NZ (1) NZ581183A (de)
PT (1) PT2154971E (de)
TW (1) TWI449525B (de)
WO (1) WO2008139271A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461194B (zh) * 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
US20120009203A1 (en) * 2010-06-29 2012-01-12 Anahid Jewett Depletion of cancer stem cells
US9763982B2 (en) 2010-06-29 2017-09-19 The Regents Of The University Of California Depletion of cancer stem cells
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
RU2014102089A (ru) 2011-06-24 2015-07-27 Пирамал Энтерпрайзис Лимитед Соединения для лечения видов рака, ассоциированных с папилломавирусом человека
CN105530931B (zh) * 2013-07-12 2019-11-08 皮拉马尔企业有限公司 用于治疗黑素瘤的药物组合
US9901574B2 (en) 2015-04-20 2018-02-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
RU2726367C2 (ru) 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3606536A4 (de) 2017-04-04 2020-12-16 University of Miami Biomarker für prostatakrebs und behandlung davon
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
CA3093548A1 (en) * 2018-03-12 2020-01-23 Yeditepe Universitesi A chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
RU2710273C1 (ru) * 2019-04-24 2019-12-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Фармацевтическая композиция для лечения злокачественных новообразований
CN114767669B (zh) * 2022-05-20 2023-07-04 湖南省中医药研究院 一种P-gp抑制剂及其提取方法和应用
CN116083566B (zh) * 2022-09-06 2025-10-17 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) Cdk14的抑制剂在卵巢癌紫杉醇化疗耐药中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) * 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7915301B2 (en) * 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
BR0316004A (pt) * 2002-11-06 2005-09-13 Cyclacel Ltd Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
CN1889943A (zh) * 2003-12-08 2007-01-03 美国亚利桑那大学董事会 协同抗癌组合物
AU2006223257A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof

Also Published As

Publication number Publication date
CN101677567B (zh) 2013-06-19
AR066564A1 (es) 2009-08-26
DK2154971T3 (da) 2012-04-02
ES2380129T3 (es) 2012-05-08
TW200913991A (en) 2009-04-01
JP5688288B2 (ja) 2015-03-25
AU2007353129A1 (en) 2008-11-20
CA2687204C (en) 2015-11-24
TWI449525B (zh) 2014-08-21
WO2008139271A2 (en) 2008-11-20
IL202014A0 (en) 2010-06-16
EP2154971A4 (de) 2010-05-19
PT2154971E (pt) 2012-04-10
KR20100017763A (ko) 2010-02-16
BRPI0721626A2 (pt) 2013-01-22
CA2687204A1 (en) 2008-11-20
MX2009012155A (es) 2010-01-15
US20100305057A1 (en) 2010-12-02
JP2010526862A (ja) 2010-08-05
EP2154971A2 (de) 2010-02-24
CN101677567A (zh) 2010-03-24
EP2154971B1 (de) 2011-12-28
AU2007353129B2 (en) 2014-02-20
NZ581183A (en) 2012-03-30
KR101403100B1 (ko) 2014-06-19
WO2008139271A3 (en) 2009-04-23
US8822526B2 (en) 2014-09-02
IL202014A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
ATE538652T1 (de) Synergistische pharmazeutische kombination für die behandlung von krebs
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2121139T3 (da) Formulations for cancer treatment
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
PL2152237T3 (pl) Nowa kompozycja farmaceutyczna
EP2415763A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von glaukom
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
BR112012002265A2 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
SMT201500189T1 (it) Ligandi sigma per la prevenzione o il trattamento del dolore indotto da chmioterapia
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0811919A2 (pt) Medicamento para tratamento do mal de alzheimer
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.